鈥淭his is used to hope to prevent the spread of the virus. He was not involved in the trial but in theory because of the high risks of his age and obesity potentially it will offer some benefits,鈥� said Dr. Kleiner.

-

鈥淭his particular trial has a combination of two antibodies, they're what are called non competing, so they're actually working against different parts of the protein. The theory of that is if the virus did mutate against one of them, potentially the other antibody that鈥檚 still in the cocktail would still prevent transmission.鈥�

- Latest on COVID Drug and Vaccine Trials: An Expert Panel with Trial Site Doctors and the American Medical Association

鈥淢ost of that data is coming from the treatment studies, not so much the prophylaxis studies, there are patients 鈥� particularly young children who might have very high levels in their nose but have very minor symptoms, so the viral load doesn鈥檛 necessarily correlate with the symptoms. The studies try to capture both symptoms scores and virus quantitation, so as we learn more about the use of the medications, hopefully, we鈥檒l have better data.鈥�

- Latest on COVID Drug and Vaccine Trials: An Expert Panel with Trial Site Doctors and the American Medical Association